708 patients received at least one Ra223 injection and 683 (548 symptomatic, 135 asymptomatic) received enough treatment to be evaluated. Asymptomatic patients received fewer prior treatments of abiraterone (25% vs 35%), enzalutamide (4% vs 8%), and docetaxel (52% vs 62%). Asmptomatic patients were more likely to complete the full treatment of 6 cycles of Ra223 (71% vs 55%). In addition, adverse events were less common in asymptomatic patients.
Overall survival was longer in asymptomatic patients (median 20.5 months vs 13.5 months for symptomatic). Asymptomatic patients were more likely to show alkaline phosphatase (ALP) normalization (59% vs 34%).
Presented By: Joe M. O’Sullivan from The Center for Cancer Research and Cell Biology, Queen’s University, Belfast, and the Northern Ireland Cancer Center, Belfast, Northern Ireland
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.